7月10日 - ** 制药商 Pacira BioSciences PCRX.O 股价盘前下跌 ~5% 至 22.02 美元
** PCRX在向美国证券交易委员会提交的一份文件（(link)）中称，在为其疼痛治疗产品EXPAREL升级到更大的生产车间后，该公司将在圣地亚哥科学中心裁员71人，约占员工总数的8%。
** EXPAREL 是一种经 FDA 批准用于术后镇痛的药物，这意味着它有助于减轻或预防术后疼痛，使病人在康复过程中感觉更舒适。
** 该公司表示，预计 2025 年第三季度将因遣散费和相关费用产生 240 万至 280 万美元的税前支出。
** 截至上一交易日收盘，PCRX股价年累计上涨约23
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.